Zymo Research Announces Strategic Partnership with biomodal to Deliver Next-Gen Multiomic Insights

November 16, 2025

Irvine, CA (November 18, 2025) — Zymo Research, a global leader in epigenetics and next-generation sequencing (NGS), has entered a strategic partnership with biomodal, an omics-based life sciences technology and analytics company. As part of biomodal’s certified provider network, Zymo Research’s NGS Services division is now authorized to deliver services using biomodal’s duet multiomics solution evoC and duet multiomics solution +modC, enabling researchers to access comprehensive genetic and epigenetic insights from a single DNA sample.

 

This partnership expands Zymo Research’s industry-leading NGS Services portfolio and strengthens its leadership in epigenomics by introducing a powerful new capability: enzymatic sequencing of both 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC). As an important epigenetic biomarker with emerging roles in development, aging, and disease, 5hmC has historically been difficult to detect with precision. Now, researchers can differentiate between cytosine modifications and obtain the complete DNA sequence in a single assay. This integrated approach provides critical insights into gene regulation and enables more accurate biomarker discovery.

 

“Our partnership with biomodal brings transformative multiomic insights into the hands of researchers and clinicians,” said Dr. Keith Booher, Director of NGS Services, Zymo Research. “For the first time, scientists can analyze 5mC, 5hmC, and the four canonical bases from a single library prep. This represents a major technological innovation for epigenetics and biomedical research.”

 

Zymo Research now offers two distinct service formats that empower researchers to move beyond the 4-base genome and achieve accurate, reproducible results:

  • Simultaneous analysis of 5hmC, 5mC, and genetic sequence from a single DNA library—enabling comprehensive, enzymatic epigenetic profiling and complete genetic sequencing. This service integrates biomodal’s duet evoC assay and data analysis software with Zymo Research’s optimized DNA extraction, sequencing, and bioinformatics expertise.
  • Joint sequencing of 5mC and the four canonical bases, providing accurate identification of genetic changes by decoding bases on the original and copy strands. This service combines biomodal’s duet +modC library prep assay and data analysis package with Zymo Research’s proven sample prep technologies and streamlined sequencing workflow.

 

These services are compatible with a wide range of complex sample types and are fully supported by Zymo Research’s end-to-end NGS services infrastructure, from extraction through sequencing and bioinformatics analysis.

 

Together, Zymo Research and biomodal are delivering a powerful, unified solution to decode the complexity of the epigenome. This partnership brings the scientific community a new level of access to the full 6-base genome—a level of insight that goes beyond standard sequencing to include not just the four canonical DNA bases, but also two powerful epigenetic biomarkers: 5mC and 5hmC.

 

“biomodal is proud to announce Zymo Research as a bCSP. By combining biomodal’s advanced multiomic technology with Zymo Research’s commitment to delivering exceptional data and support, we are creating new opportunities to accelerate breakthroughs in health and disease research,” said Dr. Donna McDade Walker, VP of Product Management & Global Marketing at biomodal.

This novel workflow enables deeper, more informative studies in oncology, neurobiology, non-invasive prenatal testing, immunology, aging, and precision medicine. By integrating complementary strengths in chemistry, technology, and service infrastructure, Zymo Research and biomodal are helping researchers gain deeper insights into gene regulation, cell state, and disease progression.

 

Explore Zymo Research’s comprehensive portfolio of NGS services: https://www.zymoresearch.com/pages/services

 

 

 

About Zymo Research Corp.  

Zymo Research, a privately owned biotech company founded in 1994, is a global leader in molecular tools for life sciences. Driven by the principle “The Beauty of Science is to Make Things Simple,” Zymo Research is dedicated to developing innovative solutions that address complex scientific challenges. 

 

Known also as The Epigenetics Company, Zymo Research offers a comprehensive range of technologies, including solutions for sample collection, DNA/RNA purification, library preparation, microbiomics, transcriptomics, epigenomics, genomics, and Next-Generation Sequencing (NGS) services. 

 

In addition to its cutting-edge technologies, Zymo Research is committed to sustainability. By engineering environmentally friendly solutions, the company strives to reduce waste and contribute to a more sustainable future through scientific innovation. 

 

For more information, please visit www.zymoresearch.com and follow on Facebook, LinkedIn, X (Twitter), and Instagram.